Skip to content
value.today
Lantern Pharma Inc. logo

Lantern Pharma Inc.

LTRN
$12 Mmarket cap on Oct 30, 2026-74.8% since Jan 2024
1M
-34.7%
Compare
World rank
#25,645
Revenue
—
For year ending December-2025
Net income
$-17 M
SEC filing
Employees
16
As of December 31, 2025
SEC filing

Lantern Pharma Inc. in brief

Lantern Pharma Inc. is a listed company in the Biotechnology industry, based in Dallas, Texas, USA. Its market value was $12 M on 30 October 2026, which makes it the 25,645th largest listed company in the world and the 4,269th largest in the USA on this site. It employs about 16 people and Panna Sharma is its chief executive. Its shares trade under the symbol LTRN (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Lantern Pharma Inc.

We are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Our development portfolio includes three clinical stage oncology focused product candidates and consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that we are developing with the assistance of our proprietary A.I. platform and our biomarker driven approach. Our A.I. platform, known as RADR®, currently includes more than 200 billion data points, and uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. This data-driven, genomically-targeted and biomarker-driven approach allows us to pursue a transformational drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates at what we believe is a fraction of the time and cost associated with traditional cancer drug development. On average, our newly developed drug programs have been advanced from initial A.I. insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-$2.5 million per program.

From the company's annual report filed with the US SEC: read the report

Lantern Pharma Inc. timeline

2 events, 2019–2020
  1. 2019
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2020
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 12 June 2020; shares registered for exchange trading on 8 June 2020.

Events of Lantern Pharma Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$33 M$65 M$98 M$131 M202120222023202420252026

World rank over time

▼ down 8,204 places since 2021
2021-01-01: #17460#17,46020212022-01-07: #23874#23,87420222022-12-25: #24160#24,16020222023-07-30: #25190#25,19020232024-01-05: #25373#25,37320242026-03-08: #11603#11,60320262026-08-01: #20502#20,50220262026-09-24: #24694#24,69420262026-10-30: #25664#25,6642026

Rank in USA: #3,582 (Jan 2021) · #4,590 (Jan 2022) · #4,643 (Dec 2022) · #4,727 (Jul 2023) · #4,110 (Jan 2024) · #2,250 (Mar 2026) · #3,845 (Aug 2026) · #4,136 (Sep 2026) · #4,272 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.8×
Free cash flow yield
-135.2%
Net margin
—
Operating margin
—
Return on equity
-262.2%
Liabilities / assets
40.8%
Profit per employee
$-1.1 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2019: revenue —, net income $-2M—FY19Fiscal year ending Dec 2020: revenue —, net income $-6M—FY20Fiscal year ending Dec 2021: revenue —, net income $-12M—FY21Fiscal year ending Dec 2022: revenue —, net income $-14M—FY22Fiscal year ending Dec 2023: revenue —, net income $-16M—FY23Fiscal year ending Dec 2024: revenue —, net income $-21M—FY24Fiscal year ending Dec 2025: revenue —, net income $-17M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-18M$-17M—
Dec 2024——$-22M$-21M—
Dec 2023——$-18M$-16M—
Dec 2022——$-14M$-14M—
Dec 2021——$-13M$-12M—
Dec 2020———$-6M—
Dec 2019———$-2M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-16M$0M$-16M$-1.57—
Dec 2024$-18M$0M$-18M$-1.93—
Dec 2023$-14M$0M$-14M$-1.47—
Dec 2022$-13M$0M$-13M$-1.31—
Dec 2021$-11M$0M$-11M$-1.13—
Dec 2020$-6M——$-1.37—
Dec 2019$-2M——$-1.23—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue —, net income $-5M—Sep ’24Three months to Dec 2024 (from the annual report): revenue —, net income $-6M—Dec ’24Three months to Mar 2025: revenue —, net income $-5M—Mar ’25Three months to Jun 2025: revenue —, net income $-4M—Jun ’25Three months to Sep 2025: revenue —, net income $-4M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-4M—Dec ’25Three months to Mar 2026: revenue —, net income $-3M—Mar ’26Three months to Jun 2026: revenue —, net income $-7M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Lantern Pharma Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-18 M
Net income
$-17 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$11 M
Total liabilities
$5 M
Total equity
$7 M

As of December-2025

Top 43 institutional investors in Lantern Pharma Inc.#

As of Sep 30, 2026
43 institutions held 3.9 M shares (about 30.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 27.6%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Lantern Pharma Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Armistice Capital, LLC1,036,000New8.10%$1 MNov 16, 2026
2Empery Asset Management, LP543,337-299,332 (-35.52%)4.25%$1 MNov 16, 2026
3CM Management, LLC500,0000 (0.00%)3.91%$1 MNov 12, 2026
4Vanguard Capital Management LLC420,286-4,832 (-1.14%)3.29%$0 MNov 13, 2026
5Renaissance Technologies LLC368,407+77,368 (+26.58%)2.88%$0 MNov 12, 2026
6BIOS Capital Management, LP235,895-13,502 (-5.41%)1.85%$0 MNov 13, 2026
7Two Sigma Investments, LP141,713New1.11%$0 MNov 16, 2026
8UBS Group AG125,416+108,784 (+654.06%)0.98%$0 MNov 10, 2026
9Geode Capital Management, LLC101,643-1,176 (-1.14%)0.80%$0 MNov 6, 2026
10Vanguard Fiduciary Trust Co49,9500 (0.00%)0.39%$0 MNov 13, 2026
11Westside Investment Management, Inc.47,8500 (0.00%)0.37%$0 MNov 2, 2026
12Susquehanna International Group, LLP39,155+25,082 (+178.23%)0.31%$0 MNov 16, 2026
13HRT Financial LP30,307New0.24%$0 MNov 13, 2026
14NewEdge Advisors, LLC26,699-350 (-1.29%)0.21%$0 MNov 13, 2026
15DAVENPORT & Co LLC23,8140 (0.00%)0.19%$0 MOct 14, 2026
16State Street Corp23,6520 (0.00%)0.18%$0 MNov 12, 2026
17Horizon Kinetics Asset Management LLC22,746-2,418 (-9.61%)0.18%$0 MNov 12, 2026
18BlackRock, Inc.22,230-120 (-0.54%)0.17%$0 MNov 13, 2026
19Bank of New York Mellon Corp21,3010 (0.00%)0.17%$0 MNov 5, 2026
20Northern Trust Corp17,4850 (0.00%)0.14%$0 MNov 16, 2026
21Focus Partners Wealth15,4320 (0.00%)0.12%$0 MNov 12, 2026
22Squarepoint Ops LLC15,296New0.12%$0 MNov 9, 2026
23XTX Topco Ltd15,244-2,171 (-12.47%)0.12%$0 MNov 16, 2026
24Cetera Investment Advisers12,2280 (0.00%)0.10%$0 MNov 13, 2026
25Jane Street Group, LLC11,670New0.09%$0 MNov 12, 2026
Show all 43: investors 26 to 43
Institutional investors 26 to 43 in Lantern Pharma Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Farther Finance Advisors, LLC8,500-2,475 (-22.55%)0.07%$0 MOct 8, 2026
27Nuveen, LLC4,102New0.03%$0 MNov 10, 2026
28BFC Planning, Inc.3,760+500 (+15.34%)0.03%$0 MNov 13, 2026
29Tower Research Capital LLC (TRC)2,982+1,820 (+156.63%)0.02%$0 MNov 16, 2026
30Vanguard Global Advisers, LLC2,3550 (0.00%)0.02%$0 MNov 13, 2026
31Simplex Trading, LLC2,171-166 (-7.10%)0.02%$0 MNov 4, 2026
32SBI Securities Co., Ltd.2,1590 (0.00%)0.02%$0 MOct 22, 2026
33Morgan Stanley602-37 (-5.79%)0.00%$0 MNov 13, 2026
34IFP Advisors, Inc552New0.00%$0 MOct 16, 2026
35Northwestern Mutual Wealth Management Co5000 (0.00%)0.00%$0 MNov 13, 2026
36Colonial Trust Advisors400New0.00%$0 MNov 10, 2026
37Entrust Financial LLC400-100 (-20.00%)0.00%$0 MNov 4, 2026
38Osaic Holdings, Inc.225+5 (+2.27%)0.00%$0 MNov 12, 2026
39PlanVest Financial, Inc1000 (0.00%)0.00%$0 MNov 9, 2026
40FMR LLC47New0.00%$0 MNov 10, 2026
41Barclays PLC38+32 (+533.33%)0.00%$0 MNov 6, 2026
42Group One Trading LLC230 (0.00%)0.00%$0 MNov 10, 2026
43Key Financial Inc20 (0.00%)0.00%$0 MNov 2, 2026

Mutual funds holding Lantern Pharma Inc.#

9 funds hold shares worth $2 M (about 4.0% of the company). Since their previous reports 3 added shares and 7 sold, buying $0 M net.
Mutual funds holding Lantern Pharma Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.338,385$1 M2.6%<0.01%+35%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.81,101$0 M0.63%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC47,619$0 M0.37%<0.01%+3.8%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC15,273$0 M0.12%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC11,259$0 M0.09%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC6,838$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.4,832$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP1,924$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP643$0 M<0.01%<0.01%−38%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 9 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Lantern Pharma Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$100 K
2 purchases, 2 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$100 K
open market only
Insiders on file
13
since
$100 K-$676 K$0Nov 2023: bought $0 (0 trades), sold $500 K (4 trades)Nov 23Jan 2024: bought $0 (0 trades), sold $247 K (6 trades)Jan 24Feb 2024: bought $0 (0 trades), sold $676 K (18 trades)FebMay 2024: bought $0 (0 trades), sold $189 K (12 trades)MayMay 2025: bought $0 (0 trades), sold $168 K (30 trades)MayJun 2025: bought $0 (0 trades), sold $332 K (40 trades)JunMay 2026: bought $100 K (2 trades), sold $0 (0 trades)May
Bought (open market)Sold (open market)Hover a month for the totals
Lantern Pharma Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Lee Troy SchalopDirectorBuy+48,544$2.060—48,544Form 4
filed D. Jeffrey KeyserDirectorBuy+48,544$2.060$100 K94,303Form 4
filed BIOS Fund II QP, LP10% ownerSellindirect-7,206$3.090—189,117Form 4
filed BP Directors, LP10% ownerSellindirect-7,206$3.090$22 K189,117Form 4
filed BIOS Fund II QP, LP10% ownerSellindirect-12,319$3.090—323,335Form 4
filed BP Directors, LP10% ownerSellindirect-12,319$3.090$38 K323,335Form 4
filed BP Directors, LP10% ownerSellindirect-1,903$3.090$6 K49,957Form 4
filed BIOS Fund II QP, LP10% ownerSellindirect-1,903$3.090—49,957Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Lantern Pharma Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
924,479
8.2% of shares · 2.68 days to cover
Buybacks, Q4 2022
$0M
Q4 2022
Shares sold short, last 24 reportsAll stocks →
Lantern Pharma Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2022Q4 2022$0M
Q3 2022Q3 2022$0M
Q2 2022Q2 2022$0M
Q1 2022Q1 2023$2.5M

Trading halts

  • 2025-09-16 12:25 UTC, code T3, resumed 12:45 UTC

Fails to deliver

  • : 102 shares at $0.73
  • : 32 shares at $0.77
  • : 151 shares at $1.39
  • : 495 shares at $1.55
  • : 433 shares at $1.93

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Lantern Pharma Inc. scorecard#

Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.8×Price to book 1.8× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-135.2%Free cash flow is -135.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.57 vs -1.93Diluted EPS -1.57 in fiscal 2025 against -1.93 the year before (report's currency).
    • ✗Net income higher than five years earlier-$17 M-$17 M in fiscal 2025 against -$6 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$17 MNet income -$17 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-123.5%-123.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.40 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year1.3%Diluted shares up 1.3% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Lantern Pharma Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Lantern Pharma Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Research and development11,51416,12611,8948,6037,5712,243r—
General and administrative6,4646,0915,9835,8305,0213,6651,475
Operating expenses17,97822,21617,87814,43312,5925,9082,428
Operating income−17,978−22,216−17,878−14,433−12,592——
Other non-operating income (expense)4216931,151−32161——
Net income including minority interests————−12,363−5,908r2,428
Minority interests' share of net income————12,3635,908—
Net income attributable to shareholders−17,119−20,781−15,962−14,260−12,363−5,908−2,428
Earnings per share, basic-1.57-1.93-1.47-1.31-1.13-1.37-1.23
Earnings per share, diluted-1.57-1.93-1.47-1.31-1.13-1.37-1.23
Shares, weighted average (basic)1111111111——
Shares, weighted average (diluted)11111111114.32.0
Balance sheet
Cash and cash equivalents4,4237,51121,93837,20251,52419,2291,232
Short-term investments5,69616,50219,36517,99419,201——
Other current assets6841,2352,0392,9851,9911,0080.8
Current assets10,80325,24843,34158,72372,71620,2371,233r
Property, plant and equipment3247524830228.8
Right-of-use (leased) assets7624022848186——
Total assets11,03625,57243,64858,83673,95020,3601,433
Accounts payable4,4234,1402,5052,7452,174552—
Current liabilities4,5024,3312,6782,7982,326552489
Lease liabilities (non-current)—5361—53——
Total liabilities4,5024,3842,7402,7982,379661489
Retained earnings−93,145−76,026−55,244−39,283−25,023−12,660−6,752
Shareholders' equity6,53421,18840,90856,03871,57119,699943
Total equity——————943
Total liabilities and equity11,03625,57243,64858,83673,95020,3601,433
Shares outstanding11111111116.22.0
Cash-flow statement
Depreciation and amortization171715106.83.41.6
Share-based compensation6516521,017r1,188962——
Cash from operating activities−15,677−17,813−14,347−12,767−10,592−5,652−2,128
Capital expenditure−1.7−13−19−28−15——
Cash from investing activities11,0573,369−930179−19,531−16−5.7
Shares issued1,625———69,000——
Shares bought back——−500−2,482−940——
Cash from financing activities1,49867−500−2,18263,41623,6652,921
Change in cash−3,088−14,427−15,805−14,78133,29517,997787
Report10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Lantern Pharma Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$764 K
Panna Sharma
Other top executives, average
$415 K
the CEO earned 1.8× this
$100 invested is now
$71
Lantern Pharma Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Panna Sharma$764 K$779 K$415 K$71
2024Panna Sharma$1.1 M$1.0 M$646 K$75

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Lantern Pharma Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 2 · Material agreement 3 · Unregistered share sale 2 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 9

Lantern Pharma Inc.: events reported to the SEC
FiledWhat happenedFiling
Delisting notice8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officersBylaws or fiscal year changed8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Bylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 1, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Lantern Pharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2019$2 MNo. 1$2 to $10 million5equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Lantern Pharma Inc.#

1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $78 K a year.

Certified, FY2025
1
#1,973 among companies on value.today
Worker positions
1
Median wage offered
$78 K
a year, full-time
Applications filed
1
Lantern Pharma Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Digital Marketing ManagerPublic Relations Specialists1$78 K

Where: Atlanta, GA 1

Lantern Pharma Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202511$78 K1
FY202311$87 K1
FY202211$52 K1
FY202111$69 K1
FY202055$79 K5

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Lantern Pharma, Inc.

How Lantern Pharma Inc. compares in Biotechnology

  • Market cap$12 M · higher than 11% of 726
  • Price / book1.8× · lower than 61% of 534
  • FCF yield-135.2% · higher than 6% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Lantern Pharma Inc.🇺🇸$12 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Lantern Pharma Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Lantern Pharma Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Lantern Pharma Inc.? Suggest a correction